No Prescription |
 |
 | ||
|
PLETOZ Pletal |
|
| ||
No Prescription » Prescription Drugs 13 » PLETOZ Pletal Cilostazol is used to reduce the symptoms of intermittent claudication (pain in the legs that happens when walking and goes away with rest). Cilostazol helps people walk a longer distance before leg pain starts.Cilostazol comes as a tablet to take by mouth. It is usually taken two times a day. It should be taken at least 30 minutes before or 2 hours after breakfast and dinner. Follow the directions on the prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take cilostazol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Cilostazol controls the symptoms of intermittent claudication but does not cure it. It may take up to 12 weeks before you notice a benefit (increased walking distance) from cilostazol. Continue taking cilostazol even if you feel well. Do not stop taking cilostazol without talking to your doctor. Buy PLETOZ Pletal and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About PLETOZ Pletal: Product Type: Prescription Drugs 13 PLETOZ ( Pletal Generic Cilostazol ) PLETOZ (Pletal Generic Cilostazol) Pletal Generic Cilostazol 100mg caps Pletal Generic Cilostazol PLETOZ
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
